Something is wrong with the world’s most influential biomedical funding system, and universities are starting to feel it in real time.Halfway through the federal fiscal year, the National Institutes of Health (NIH) has committed only a fraction of the amount it is expected to disburse. An analysis released by the Association of American Medical Colleges showed that as of last week only $5.8 billion, about 15 percent of the estimated $38 billion budget, was owed. At the same point in the previous cycle, the figure was closer to $9 billion, as reported by the NIH Reporter site.In federal terms, “responsibility” is not a trivial promise. It is a formal signal to universities and research institutes that funds are available to be spent. The difference, therefore, is not technical; It is solid.
A delayed start is proving difficult to recover from.
Slowness did not emerge in isolation. It began with last year’s prolonged government shutdown, which effectively shut down NIH’s grantmaking machinery for the first seven weeks of the fiscal year. When funding activity resumed in December, the agency was already behind schedule.Subsequent numbers suggest a system struggling to catch up. NIH owed $1.2 billion in December, followed by $2 billion in January and February. That pace, while steady, is lower than historical trends. According to an AAMC review of NIH reporter data, the first half of this fiscal year has seen markedly lower funding activity than in any of the past five years.The concern is now less about latency and more about compression. If the pattern continues, NIH could once again be forced into a year-end sprint to meet its Sept. 30 deadline, an approach that has consequences far beyond accounting.
When speed replaces strategy.
Last year offered a preview of what this kind of sprint might look like. Faced with time constraints, the NIH cut more than half of its annual research funding in the last three months of the fiscal year.To do so, it relied heavily on multi-year grants, large, extended commitments that allowed the agency to allocate funds quickly. The trade-off was immediate: fewer new grants were awarded.This contraction is already visible this year. Since October, the NIH has issued just 1,187 new grants, 63 percent below the average at that stage over the past five years, according to AAMC data. For a research ecosystem that thrives on fresh proposals and new ideas, this decline is not just a statistic. This is a narrowing of possibilities.
Universities start to back off.
Tensions are now spreading within the campus. The Association of American Universities has identified a similar slowdown, with senior policy officials warning that the NIH is “significantly behind,” as reported by The Inside Higher Ed.This interval is shaping decisions in admissions offices and laboratories alike. Some universities have reduced the number of Ph.D. Students they enroll in life sciences. Others are offering entry with caveats, uncertain whether funding will be forthcoming. Hiring freezes have become common. Layoffs, in some cases, inevitable.These are not routine adjustments. Research universities operate on long timelines, where faculty recruitment, student enrollment, and lab investment are tightly linked to anticipated grant flows. When funding becomes unpredictable, institutions do what they must to manage risk, and that usually means pulling back.
A silent squeeze on early-career scientists
However, the greatest impact is being felt by those with the least margin for procrastination: early-career researchers. Data from the NIH and cited by the AAMC paint a clearer picture. Applications for R01-equivalent grants, often the gateway to an independent research career, increased last year. However, the awards fell. In 2024, about a quarter of applicants received funding. In 2025, this share declined significantly despite a larger applicant pool.These scientists are in their prime, typically within a decade of completing their training, often building their first labs, and working against tight professional timelines. A shorter grant cycle can set them back years or push them out of academia altogether.Ironically, this comes at a time when NIH leadership has talked about the need to support young scientists and risky ideas.
A deeper question of trust
Beyond numbers and timelines lies a more fundamental issue: trust. Biomedical research does not operate on short cycles. It depends on sustainable, predictable investment, on the assumption that viable ideas will have the time and resources they need to mature. When this assumption is weakened, its effects extend outward.Graduate enrollments are shrinking. Labs are reluctant to spread. Researchers become more careful in the questions they choose to pursue.The AAMC put it bluntly in its report: Predictable funding is essential not only for scientific progress but also for ensuring that public investments deliver meaningful returns.
Waiting for speed
There are early signs that the situation may improve. Recent approvals of funding appropriations have raised expectations that the NIH could pick up momentum in the coming weeks. Whether this acceleration will be measured and strategic, or compressed and reactive, is uncertain.For now, the system is in a holding pattern. Universities are adjusting, researchers are waiting, and the world’s largest biomedical funder is under pressure to prove that a slow start won’t define the year.Because in science, delay is rarely just delay. They are often pathways, which can reshape who can participate, which ideas advance, and how quickly discovery unfolds itself.
